Glipizide
Glipizide (Glucotrol) is a second-generation sulfonylurea used to treat type 2 diabetes. It lowers blood sugar by binding to and blocking ATP-sensitive potassium (K-ATP) channels on pancreatic beta cells, triggering insulin secretion. Because it requires functioning beta cells, it is ineffective in type 1 diabetes and loses efficacy as type 2 diabetes progresses and beta cells decline. The primary risks are hypoglycemia (particularly in the elderly) and weight gain. Glipizide is among the preferred sulfonylureas due to its shorter half-life and lower risk of prolonged hypoglycemia compared to glyburide.
Uses & FDA Indications
Glipizide is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is one of the most commonly prescribed second-generation sulfonylureas and remains a standard of care option particularly in settings where cost is a consideration — sulfonylureas are among the least expensive antidiabetic medications available.
While newer drug classes (GLP-1 receptor agonists, SGLT-2 inhibitors) have demonstrated cardiovascular and renal benefits beyond glucose lowering, glipizide retains a role for patients who need effective and inexpensive oral glucose control without the complex administration or cost of newer agents. It is particularly useful when rapid glucose lowering is needed.
Glipizide is not indicated for type 1 diabetes, diabetic ketoacidosis, or as monotherapy in patients with no residual beta-cell function. It is also not approved during pregnancy — insulin is the preferred glucose-lowering agent in gestational and pre-existing diabetes during pregnancy.
How It Works
Glipizide belongs to the sulfonylurea class, which lowers blood glucose by directly stimulating insulin secretion from pancreatic beta cells. The drug binds to the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium channel (K-ATP channel) complex on the beta-cell membrane. Binding closes these channels, causing membrane depolarization, which opens voltage-gated calcium channels, leading to calcium influx and subsequent exocytosis of insulin-containing granules.
This mechanism is glucose-independent — glipizide stimulates insulin release regardless of the prevailing blood glucose concentration. This is the fundamental basis of its hypoglycemia risk: insulin secretion is driven by drug binding rather than by physiological glucose sensing.
Among sulfonylureas, glipizide is preferred over glyburide in elderly patients and those with chronic kidney disease because it has a shorter half-life and its metabolites are pharmacologically inactive. Glyburide has active metabolites that accumulate in renal impairment, substantially increasing the risk of severe, prolonged hypoglycemia. Glipizide's metabolic profile makes hypoglycemia more predictable and manageable.
HYPOGLYCEMIA WARNING: Glipizide can cause life-threatening hypoglycemia, particularly in elderly patients, those with renal or hepatic impairment, patients who skip meals, and those using concurrent alcohol or other glucose-lowering agents. Severe hypoglycemia from sulfonylureas may require prolonged glucose administration and medical monitoring — it is not always self-limited. Counsel patients to eat consistently and recognize early hypoglycemia symptoms.
Side Effects
Common
- Hypoglycemia — the most significant adverse effect; risk increases with missed meals, alcohol, renal impairment, advanced age, and polypharmacy with other antidiabetics or medications that enhance sulfonylurea effect
- Weight gain — insulin stimulation promotes fat storage; average gain of 1–4 kg over the course of therapy; a major drawback relative to weight-neutral or weight-losing alternatives
- GI symptoms — nausea, diarrhea, constipation; more common at initiation
- Dizziness, headache — often related to blood glucose fluctuations
Less Common / Serious
- Severe prolonged hypoglycemia — particularly in elderly, renally impaired, or those with irregular nutrition; may require IV dextrose and prolonged observation
- Hyponatremia (low sodium) — sulfonylureas can enhance antidiuretic hormone activity; rare but more notable with chlorpropamide (an older sulfonylurea)
- Hepatotoxicity — rare; elevated liver enzymes have been reported
- Photosensitivity — skin reactions with sun exposure; rare
- Hematologic effects — aplastic anemia, thrombocytopenia; very rare
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Fluconazole and other CYP2C9 Inhibitors (amiodarone, fluvoxamine) | Glipizide is metabolized by CYP2C9. Inhibitors increase glipizide plasma levels, raising hypoglycemia risk significantly. | High — monitor blood glucose closely; consider reducing glipizide effect or dose |
| Beta-Blockers (propranolol, metoprolol, atenolol) | Mask tachycardia and tremor — key warning signs of hypoglycemia. Sweating is unaffected. Propranolol (non-selective) may also prolong hypoglycemia by blocking glycogenolysis. | Moderate — counsel patients on alternative hypoglycemia signs; use cardioselective beta-blockers when possible |
| Alcohol | Inhibits hepatic gluconeogenesis, worsening hypoglycemia. Alcohol may also cause a disulfiram-like flushing reaction with some sulfonylureas. | Moderate-High — advise against alcohol use, especially on an empty stomach |
| NSAIDs (especially high-dose aspirin) | Can enhance hypoglycemic effect through displacement from protein binding and inhibiting renal prostaglandin synthesis. | Moderate — monitor glucose with regular NSAID use |
| Corticosteroids, Thiazides, Phenytoin | Hyperglycemic agents that antagonize glipizide's glucose-lowering effect; may require dose adjustment or alternative therapy during steroid courses. | Moderate — monitor glucose; may need temporary insulin coverage during steroid courses |
Warnings & Contraindications
Contraindications
- Type 1 diabetes mellitus — no beta-cell function to stimulate
- Diabetic ketoacidosis — requires insulin therapy
- Hypersensitivity to glipizide or other sulfonylureas
- Pregnancy — insulin is preferred for glucose management in pregnancy
Use in Elderly Patients
Elderly patients are at heightened risk for hypoglycemia from glipizide due to reduced renal clearance, irregular meal patterns, reduced ability to perceive hypoglycemia symptoms (hypoglycemia unawareness), and polypharmacy. The American Geriatrics Society Beers Criteria lists glyburide (but not glipizide) as a potentially inappropriate medication in elderly patients specifically because of its active metabolite accumulation. Glipizide is considered the preferred sulfonylurea when this class is used in older adults, but caution and close monitoring are still warranted.
Renal Impairment
Glipizide is metabolized in the liver to inactive metabolites, which are then excreted renally. The parent drug itself is hepatically metabolized. Unlike glyburide, which has active renally-cleared metabolites, glipizide has a safer profile in mild-to-moderate renal impairment. However, in severe renal impairment (CrCl <10 mL/min), accumulation concerns arise and insulin may be preferable.
Check for hypoglycemia-enhancing interactions or contraindications with glipizide.
Check Drug Interactions →Frequently Asked Questions
Can glipizide cause low blood sugar?
Yes — hypoglycemia is the primary and most important adverse effect of glipizide and all sulfonylureas. Because glipizide stimulates insulin secretion regardless of blood glucose levels, it can cause blood sugar to fall too low, particularly when meals are skipped, during prolonged fasting, with unusual physical activity, or when combined with alcohol or other glucose-lowering drugs. The risk is highest in elderly patients, those with kidney or liver impairment (which reduce drug clearance), and patients with irregular eating habits. Symptoms include sweating, shakiness, confusion, palpitations, and in severe cases, loss of consciousness or seizures. Hypoglycemia from sulfonylureas can be prolonged and require sustained glucose replacement and medical monitoring.
Why does glipizide cause weight gain?
Glipizide promotes weight gain primarily because of its insulin-stimulating mechanism. Insulin is an anabolic hormone that promotes fat storage, reduces fat breakdown, and increases appetite. By chronically elevating insulin levels even when blood sugar is normal or only mildly elevated, sulfonylureas like glipizide create a hormonal environment that favors weight gain. This contrasts with metformin (which is weight-neutral or slightly weight-reducing) and newer agents like GLP-1 agonists (semaglutide, tirzepatide), which promote significant weight loss. Weight gain during sulfonylurea therapy is typically modest (1–4 kg) but is a recognized drawback in a condition where weight management is already challenging.
Does glipizide work in type 1 diabetes?
No. Glipizide and all sulfonylureas are ineffective in type 1 diabetes. Their mechanism depends entirely on stimulating the pancreatic beta cells to release more insulin. In type 1 diabetes, the beta cells have been destroyed by autoimmune attack and cannot respond to sulfonylurea stimulation. Type 1 diabetes requires exogenous insulin replacement; no oral antidiabetic drug that depends on beta-cell function will be effective. Similarly, glipizide loses effectiveness as type 2 diabetes progresses and beta cells are lost to glucotoxicity and lipotoxicity — a phenomenon called secondary sulfonylurea failure.